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INTRODUCTION
1. Introduction
Breast cancer is the most common cancer in women and represents the most 
common cause of cancer-related death in women worldwide1. Advances in early 
detection, prevention, risk stratification, and therapeutic strategies as well as 
supportive care for patients have resulted in important improvements in mortality 
and reduction of cancer relapse. However, around 20% of the patients will present 
metastatic disease. Advanced breast cancer is still an incurable disease with a median 
overall survival (OS) of ~3 years, while the 5-year survival of only ~25%2. The 
median overall survivals of patients with triple-negative (TNBC), hormone receptor 
(HR)-positive/HER2-negative and HER2-positive diseases are approximately 12, 
20, and 56 months, respectively3 4 5 6.
 
The need of a deeper understanding of cancer biology, inter- and intra-tumor 
heterogeneity, and as well as, the biology behind the progression of tumor cells 
toward metastasis is urgent. To date, evidence suggests that both intrinsic properties 
of breast cancer cells and host organ microenvironment participate actively to this 
matter7.
In general, detectable distant breast cancer metastases occur years, or even 
decades, after primary tumor diagnosis. These secondary lesions are supposed to 
originate from disseminated tumor cells that underwent a period of dormancy8 which 
is the result of equal rated of cell proliferation and cell death9. However, the molecular 
factors that promote the formation of detectable metastasis from disseminated tumor 
cells are largely unknown. To try to explore this phenomenon, several studies were 
conducted to identify the molecular differences between primary tumor and their 
matched metastatic lesions10. At the DNA level, although significant differences 
have been observed, the majority (80-85%) of molecular alterations are preserved. 
For example, the discordance of HER2 gene amplification by FISH in primary 
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versus metastatic tissue is 3-10%11. Similarly, at the protein level, estrogen and 
progesterone receptors by immunohistochemistry (IHC) are discordant in 13-28% of 
cases12. Despite it, these results suggest that minor but important molecular changes 
occur during metastatic progression such as ESR1 mutations13.     
The genomic revolution has transformed the landscape of clinical research in 
cancer, increasing the understanding of cancer biology, the identification of driver 
mutations as potential targets, and the mechanisms of sensitivity and resistance to 
conventional and newer targeted therapies. In terms of global gene expression, four 
main molecular subtypes [Luminal A, Luminal B, HER2-enriched (HER2-E) and 
Basal-like], and a normal breast-like group, have been identified and intensively 
studied for the last 15 years in early breast cancer14 15 16 17. Known as the “intrinsic 
subtypes of breast cancer”, these groups of tumors have revealed critical differences 
in tumor development18 19, survival20 21 22, and response to treatment23 24. Importantly, 
the information provided by the intrinsic subtypes complements and expands the 
information derived by classical clinical parameters (e.g., age, node status, tumor 
size, histologic grade) and pathologic markers [estrogen receptor (ER), progesterone 
receptor (PR), and HER2]25 26, all of which are routinely used today in the clinic to 
stratify patients for prognostic predictions and to select treatments.   
The greatest obstacles for improving the breast cancer outcomes include (1) 
the limited proportion of breast tumors found to have actionable mutations, (2) the 
need to integrative DNA- and RNA-based approaches, (3) mixed results in terms 
of patient outcomes and molecular targeted, and (4) biologic heterogeneity across 
population and  intrapatient tumor. 
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2. Intrinsic Molecular Subtypes of Breast Cancer
Breast cancer is a clinically and biologically heterogeneous disease. According 
to the expression of single biological biomarkers such as ER, PR, and HER2, breast 
cancer can be classified today into the following 4 main pathological-based groups: 
ER-positive and/or PR-positive and HER2-negative (HR+/HER2-negative), ER-
positive and/or PR-positive and HER2-positive (HR+/HER2+), ER-negative and 
PR-negative and HER2-positive (HR-negative/HER2+) and TNBC. This pathology-
based classification is routinely used in the clinic to stratify patients for prognostic 
predictions and to select treatments. 
In the last decade, gene expression profiling has had a considerable impact 
on our understanding of breast cancer biology. Nowadays, we have extensively 
characterized 4 main intrinsic molecular subtypes of breast cancer (Luminal A, 
Luminal B, HER2-E, Basal-like) and a normal breast-like group. These entities 
have shown significant differences in terms of incidence, risk factors, prognosis 
and treatment sensitivity. More importantly, these molecular entities have shown to 
provide additional prognostic and predictive information beyond pathological-based 
calissification27 28 29.
At the RNA and protein level, Luminal A and B subtypes are largely different 
according to the expression of two main biological process: proliferation/cell cycle-
related and luminal/hormone-regulated pathways. Compared to Luminal A, Luminal 
B tumors have higher expression of proliferation/cell cycle-related genes or proteins 
(e.g. MKI67 and AURKA) and lower expression of several luminal-related genes 
or proteins such as the PR and FOXA1, but not the ER, which is found similarly 
expressed between the two luminal subtypes and can only help in distinguish 
luminal from non-luminal disease. At the DNA level, Luminal A tumors show lower 
number of mutations across the genome, lower number of chromosomal copy-
number changes (e.g. lower rates of CCND1 amplification), less TP53 mutations 
(12% vs. 29%), similar GATA3 mutations (14% vs 15%) and more PIK3CA (45% 
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vs 29%) and MAP3K1 mutations (13% vs 5%) compared to Luminal B tumors. 
Interestingly, a subgroup of Luminal B tumors is found hypermethylated, and 
a subgroup of Luminal A (6.3–7.8%) and Luminal B (16.4–20.8%) tumors show 
HER2-amplification/overexpression30. 
The HER2-E subtype is characterized at the RNA and protein level by the 
high expression of HER2-related and proliferation-related genes and proteins (e.g. 
ERBB2 and GRB7), intermediate expression of luminal-related genes and proteins 
(e.g. ESR1 and PGR) and low expression of basal-related genes and proteins (e.g. 
keratin 5 and FOXC1). At the DNA level, these tumors show the highest number 
of mutations across the genome, and 72% and 39% of HER2-E tumors are TP53 
and PIK3CA mutated, respectively. Although the majority (68%) of HER2-E have 
HER2 overexpression/amplification, we should expect to identify the HER2-E 
subtype within HER2-negative disease. Interestingly, the HER2-E subtype has been 
found uniquely enriched for tumors with high frequency of APOBEC3B-associated 
mutations. APOBEC3B is a cytidine deaminase, which converts cytosine to uracil 
during RNA editing and retrovirus or retrotransposon restriction, and may induce 
mutation clusters in human tumors31. Several studies have now linked APOBEC 
genetic signatures with the HER2-E subtype in breast cancer32. Intriguingly, both 
the APOBEC signatures and the HER2-E profile have been associated with high 
mutational burden and high expression of immune genes and immune infiltration. 
The Basal-like subtype is characterized at the RNA and protein level by the 
high expression of proliferation-related genes (e.g. MKI67) and keratins typically 
expressed by the basal layer of the skin (e.g. keratins 5, 14 and 17), intermediate 
expression of HER2-related genes, and very low expression of luminal-related 
genes. At the DNA level, these tumors show the second highest number of mutations 
across the genome, mostly are hypomethylated, and 80% and 9% of Basal-like 
tumors are TP53 and PIK3CA mutated, respectively. BRCA1-mutated breast cancer 
is associated with Basal-like disease. Finally, HER2 overexpression/amplification is 
found in 2.1–17.4% of tumors with a Basal-like profile.
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a. Subtype distribution within pathology-based groups
In 2009, Parker and colleagues introduced a clinically applicable gene 
expression-based test, known as PAM50, which identifies the main breast cancer 
intrinsic molecular subtypes in formalin-fixed paraffin embedded tumor tissues 
by using 50 genes33. Since then, this assay has allowed the identification of these 
molecular entities across a large number of studies, including tumor samples from 
various phase III clinical trials. Among them, we have finally selected 31 trials in 
which PAM50 and pathological markers were assessed in primary breast cancer. The 
characteristics used to define clinicopathological subtype were IHC evaluation for 
hormone receptors and IHC and/or FISH results for HER2. 
In order to assess the concordance between these two classifications and 
to understand the biologic heterogeneity of breast cancer, we have combined the 
data across these independent cohorts for a total of 21,113 samples. We defined 
clinicopathological subtype category as Luminal (HR+/HER2-), Luminal/HER2+ 
(HR+/HER2+), HER2+ (HR-/HER2+) and TNBC (ER-/HER2-). All tumors were 
assigned to an intrinsic molecular subtype Luminal A (LumA), Luminal B (LumB), 
HER2-E, Basal-like, and Normal-like group. The majority studies have performed 
a standardized version of the PAM50 assay (RT-qPCR-based or nCounter-based), 
while others have performed the microarray-based version of the PAM50 assay. 
HR and HER2 statuses, and PAM50 data, were available in 16,286 tumors. In 
the other 22.86% (4,827 out of 21,113) we do not have complete information about 
ER, PR or HER2 expression. The distribution of the pathology-based groups in this 
combined dataset was as follow: 46.26% (n=9,768) HR+/HER2-negative, 9.80% 
(n=2,069) HER2+/HR+, 7.30% (n=1,542) HER2+/HR-negative, 13.77% (n=2,907) 
TNBC, 8.83% (n=1,865) HER2+, and 14.03% (n=2,962) HR+. The distribution of 
the intrinsic subtypes in this combined dataset was as follows: 38.60% (n=8,151) 
Luminal A, 24.85% (n=5,248) Luminal B, 18.97% (n=4,004) HER2-enriched, 
14.33% (n=3,025) Basal-like and 3.25% (n=685) Normal-like (Fig. 1). 
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Within each pathology-based group, all the intrinsic molecular subtypes were 
identified, albeit with different proportions. In HR+/HER2-negative disease, 5.64% 
and 2.24% of tumors were identified as HER2-enriched and Basal-like, respectively 
(Fig 1B). In TNBC, 10.59%, 3.53% and 2.06% were identified as HER2-E, Luminal 
A and Luminal B, respectively (Fig. 1C). Finally, 45.35% of HER2+ tumors were 
not HER2-E (Fig. 1D). Subtype distribution within HER2+ disease was not entirely 
explained by HR status. Within HER2+/HR+ disease, 31.64% and 2.46% of the 
tumors were HER2-E and Basal-like, respectively (Fig. 1E). Within HER2+/HR-
negative disease, 13.82%, 6.16% and 2.08% were identified as Basal-like, Luminal 
A and Luminal B, respectively (Fig. 1F).
Fig. 1. Molecular heterogeneity of early breast cancer. Intrinsic subtype distribution (A) in global 
cohort; (B) in HR+/HER2-; (B) in HR+/HER2-; (C) in HR-/HER2-; (D) in HER2+; (E) HER2+/
HER2+; and (F) HR-/HER2+
This pooled analysis finally demonstrated two relevant situations: 1) The 
clinicopathological classification should not be considered synonymous of intrinsic 
subtype profile, suggesting that the two methods currently used to define breast 
cancer characteristics should not be considered the same; 2) breast cancer is a 
heterogeneous disease and all the intrinsic molecular subtypes is represented in each 
classical subgroup. 
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b. Clinical implications between molecular subtypes and pathological 
classification:
HR+/HER2-negative versus non-Luminals
Luminal breast cancer represents about 70% of all new diagnosis34. These 
patients have the best prognosis but, despite the benefit of endocrine therapy, 
recurrence appears in approximately 10-15%35. PAM50 classification suggests that 
it could be useful to predict both prognostic and predictive benefit deriving from the 
use of hormonotherapy in adjuvant setting, offering the possibility to personalize 
treatment for luminal breast cancer patients.
In neoadjuvant setting Ki67 expression has been used as a surrogate indicative 
of the effect of endocrine treatment outcome. ACOSOG Z1031 trial36 assessed the 
preoperative aromatase inhibitor treatment. Basal-like and HER2-E patients presented 
high pre- and post-treatment Ki67 levels consistent with endocrine resistance. And 
both Luminal A and Luminal B tumors were highly endocrine-therapy responsive, 
however Luminal B had significantly higher post-treatment Ki67 levels, according 
with the worse prognosis associated with this subtype. In the same line, Dunbier et 
al.37 also showed that Luminal A and B obtained similar benefit from neoadjuvant 
anastrozole treatment, despite Luminal B initially having higher levels of Ki67, 
while Basal-like and HER2-E presented poor reductions in Ki67 upon treatment, so 
poorer responses. 
Adjuvant endocrine therapy is the backbone of systemic treatment in hormone 
receptor positive breast cancer. In order to assess for both prognostic and predictive 
value of PAM50, it was identified in a cohort of premonopausal women with primary 
breast cancer (NCIC CTG MA.12)38 where they were randomized of tamoxifeno 
vs placebo. The intrinsic subtypes analysis were prognostic for both DFS and OS, 
luminal subtypes presented a statistically significant benefit from adjuvant tamoxifen 
16 · Primary and metastatic breast cancer
(HR: 0.52, p=0.009). In particular, patients diagnosed with HER2-E subtype were 
shown to have the lowest benefit while the Luminal A the highest benefit deriving 
from the use of tamoxifen. 
A similar analysis to evaluate response to multi-agent neoadjuvant chemotherapy 
was also performed in the same setting of patients. Data demonstrated that non-
Luminal (Basal-like and HER2-E) showed higher pCR rates than luminals (Luminal 
A and B) (30% vs 8-9%)39. 
According to the data presented, PAM50 analysis seems to be able to screen 
patients who will really benefit from hormonotherapy rather than chemotherapy. So, 
in patients with HR+/HER2-negative PAM50 risk of recurrence score associated with 
other clinicopathological parameters could provide a relevant tool to take decisions 
about adjuvant systemic treatment40. To further support this hypothesis, PAM50 assay 
was performed in a cohort of postmenopausal luminal patients who participated in 
the ABCSG-8 trial (5 years of adjuvant tramoxifen vs tamoxifen 2 years followed by 
anastrozole for 3 years without chemotherapy). DFS analysis showed a significantly 
difference between Luminal A and B (HR: 2.49, p<0.001). The 15-year late DFS 
estimated were 92.8% for Luminal A and 86.2% for the luminal B, this magnitude of 
prognostic differences was greater between ROR low- and high-risk groups (absolute 
risk distant recurrence of 2.4% in low ROR and 17.5% in the high ROR group)41. So 
both, ROR groups and breast intrinsic subtype demonstrated clinically meaningful 
differences with respect to early and late risk of distant recurrence. Therefore, with 
this evidence there is a significant and clinically relevant discrimination between 
these two groups. This finding could help to avoid unwarranted overtreatment. The 
identification of a toll able to discern whom patient will benefit from only hormonal 
therapy from whom will not, is fundamental to personalize treatment, avoiding 
chemotherapy in those patients who will not be sensitive to this treatment and who 
will only benefit from an endocrine approach.
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In advanced disease, endocrine therapy is the preferred option for luminal 
breast cancer. Nowadays, in the presence of visceral disease, unless there is proven 
visceral crisis or endocrine resistance. In 2016 the first study reporting the prognostic 
and predictive value of intrinsic subtype in first-line HR+ metastatic breast cancer 
was published. Interestingly, it was possible to observe that the identification of 
intrinsic subtypes could drive treatment. In particular, it was observed that those 
patients diagnosed with HR+/HER2- disease but with a HER2-E profile according 
to PAM50, may finally benefit from the combination of endocrine therapy with 
Lapatinib (median progression free survival, 6.49 vs 2.60 months, p= 0.02)42. This 
event could justify the clinical relevance of the identification of the intrinsic subtype 
in advanced disease to plan personalized treatment. 
HER2-E versus HER2+
HER2 overexpression or amplification is known to be an independent poor 
prognostic factor but it also recognized to be a predictive factor of response to 
anti-HER2 treatment. Classically randomized clinical trials have demonstrated the 
clinical efficacy of trastuzumab plus chemotherapy in treatment of HER2+ breast 
cancer disease. When a HER2 positive breast cancer is newly diagnosed and treated 
with trastuzumab plus chemotherapy, the DFS and OS rates expected are 84% and 
92% at five years43. However, heterogeneity of this subset of breast cancer has an 
impact in responses and clinical outcomes. 
Nevertheless, the prognostic value of HER2 status disappeared when subtypes 
were taken into account in the absence of HER2 targeting, each intrinsic subtypes 
showed similar survival regardless of their HER2 status44 45. Several trials in 
neoadjuvant and adjuvant setting have test the implication of molecular subtype in 
predicting treatment responses:
18 · Primary and metastatic breast cancer
1. Neoadjuvant Treatment
Neoadjuvant setting allows direct and early observation of the response to 
treatment. This approach provides a potential surrogate marker as pCR. Some trials 
have been used to assess the capability of intrinsic molecular subtype to predict 
tumor response. 
A retrospective analysis of NOAH trial showed that HER2-E disease presents 
a high response rate with the addition of trastuzumab at the chemotherapy regimen. 
The combination benefit was observed also in terms of DFS in the HER2-E subtype 
(HR= 0.43) compared with non-HER2-E tumors (HR= 0.87)46. 
Combined administration of two different HER2-targeted agents has been tested. 
In PAMELA trial, a phase II single group, was assessed the efficacy of dual HER2 
blockade (trastuzumab plus lapatinib) without chemotherapy. HER2-E subtype was 
associated with pCR compared with patients who had non-HER2-E profile (41% 
vs 10%), this finding was independent of hormone receptor status47. The use of 
antiHER2 blockades in neoadjuvant setting was also evaluated in the NeoALTTO, 
a phase III randomized clinical trial, compareing trastuzumab, lapatinib, or the 
combination followed by the addition of paclitaxel. The expression of ERBB2 was 
the most significant predictor of pCR, followed by HER2-E subtype. A third clinical 
trial, CherLOB phase II study48, evaluated the impact of tumor-related and immune-
related diversity of HER2+ disease on the response to neoadjuvant chemotherapy 
plus trastuzumab, lapatinb or their combination. In this case, the highest rate of 
pCR was observed for the HER2-E (50%), followed by Basal-like, Luminal B and 
Luminal A (p= 0.026). In agreement with these results, HER2-E achieved the greater 
pCR (70%), compared with luminal A (34%) and B (36%) in CALGB40601 trial. 
This is a randomized phase III trial49, where was examined the impact of trastuzumab 
plus lapatinib added to paclitaxel. 
Introduction · 19
In conclusion the molecular diversity of HER2+ breast cancer disease was 
reflected in PAM50 subtype, showing different response to neoadjuvant treatment.
2. Adjuvant Treatment
In the N9831 trial50, HER2+ patients were analyzed to assess the association 
between intrinsic subtype and clinical outcome. The PAM50 subtypes were 
statistically significantly associated (irrespective of therapy) with DFS. Patients with 
Basal-like tumors showed worse DFS compared with the others subtypes. In the arm 
with chemotherapy alone, there was no statistically significant association between 
subtypes and DFS. However, a statistically significant association was observed 
between survival outcome and intrinsic subtype among patients who received 
trastuzumab and Basal-like group showed less benefit than the others subtypes (HR= 
1.06, p=0.87). A possible answer to these results could be that in NSABP B-3151 (a 
randomized phase III clinical trial to compare chemotherapy alone or chemotherapy 
plus trastuzumab) all PAM50 intrinsic subtypes received benefit from trastuzumab 
treatment in terms of DFS. Both the HER2-E subtype and the non-HER2-E subtype 
improved the outcomes, the HR for trastuzumab arm in the HER2-E subtype was 
0.44, and in the non-HER2-E was 0.47, p< 0.001. However, both studies were limited 
in power by the relative small number of Basal-like tumors. Further investigations 
are needed.  
TNBC versus Basal-like
Triple negative breast cancer is pathologically defined by the absence of HR 
and HER2 expression. This subgroup benefits only from chemotherapy, there 
is no predictive factors of response to use targetable drugs for these group of 
patients. Several clinical trials with multi-agent chemotherapy have evaluated the 
ability of intrinsic subtype to predict response and/or survival in early disease. In 
GEICAM2006-03 and MDACC neoadjuvant trials52 were assessed the pCR, none 
of the intrinsic subtype evaluated was found significantly associated with pCR. 
However, among patients with basal-like phenotype, low expression of the luminal 
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A signature and high expression of proliferation score were statistically significant 
associated with pCR. In general, among the different pathological subtypes, the 
Basal-like shows consistently greater pCR rates.  
To predict DFS in adjuvant treatment, PAM50 were analyzed in TN breast 
cancer patients from GEICAM/9906. Within TN breast cancer of the basal-like 
subtype, these two signatures (the low expression of luminal A and high expression 
of proliferation score), were confirmed a statistical association with DFS. 
In metastatic setting, the TNT clinical trial compared treatment with carboplatin 
and docetaxel, both standard chemotherapy. PAM50 analysis showed a better 
objective response rate in non-basal subtypes with docetaxel (73.7%) than with 
carboplatin treated group (16.7%)53. And there was no difference between Basal-like 
group. Thereby, sub-classification of TN breast cancer into intrinsic subtype can help 
to identify prognostic and predictive biomarkers.
As conclusion, basing on these data, it is possible to suggest that multigene 
assays could provide prognostic and predictive information beyond pathological 
parameters and may support more-informed treatment decision54. The molecular 
subtypes of breast cancer significantly extend our knowledge about behavior of the 
disease. This makes necessary that in future clinical trials should consider stratifying 
patients by intrinsic molecular subtype.
3. Tumor and microenvironment alteration during metastasis
Metastasis frequently develops years after the removal of a primary tumor, from 
a minority of disseminated tumor cells (DTCs) that survived as latent entities through 
unknown mechanism. Before diagnosis and treatment, primary tumors may release 
large numbers of cancer cells into the circulation. Although a majority of the DTCs 
perish in the blood-stream or soon after infiltrating distant organs, a minority may 
survive as latent seeds in host tissues. Thereby, patients who are clinically considered 
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disease-free after cancer treatment may carry thousands DTC in the bone marrow 
and other organs as liver, lung or brain. 
Latent metastasis is a major concern in the clinic, up to know, very little is 
known about the nature of dormant DTCs and the mechanisms that allow these cells 
to remain quiescent, evade immunity, retain tumor-initiating capacity, and evolve 
into aggressive metastasis. 
One hypothesis is that DTCs are tumor-initiating cells that enter in quiescence 
by the action of growth inhibitory signals from the host tissue stroma. However, 
organs that host DTCs, such as the bone marrow, liver, and lungs, support cell 
proliferation as part of their normal tissue homeostasis and regenerative processes, 
raising questions as to whether stromal growth inhibitory signals are persistent 
enough to enforce long-term metastatic latency55.
Another important point, is the role of immunity in latent metastasis. The 
interplay between cancer cells and the immune system plays a crucial role in tumor 
progression. Metastatic latency may therefore require DTCs to be in equilibrium 
with the immune system.  
a. The immune landscape of breast cancer
A fundamental role of the immune system is maintenance of tissue homeostasis by 
continuous immunosurveillance and initiation of inflammatory reactions that involve 
the activation of innate and adaptive immune cells. Neoplastic transformation alters 
the orderly structure of tissues and induces immune responses that can eliminate 
incipient tumors. However, immunocompetent individuals also develop cancers in 
spite of the immunosurvillance. In these situations malignant cells escape immune 
control and a tumor develops56. Three different parameters are taken in account to 
evaluate immune response in solid tumors, such as tumor infiltrating lymphocyte, 
mutation burden and PD-L1 expression.
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The host immune response
Tumor cells suffer several genomic alterations, generating neoantigens that can 
be identified by the immune system. The interaction between the immune system 
and tumor cells, also called immunoediting, goes through three phases: elimination, 
equilibrium, and escape. In the elimination process, the innate and adaptive arms of 
the immune system recognize incipient cancer cells by this neoantigens presented on 
their surface in association with MHC-I or by the distress signals usually expressed 
by transformed cells that have undergone chromosomal changes (aneuploidy or 
hyperploidy) and eliminate them.  
Equilibrium is reached when the immune system fails to eliminate the transformed 
cells but stops them from progressing. This can be conceived as the dormancy phase 
of cancer. This phase is mediated by equilibrium between cells and cytokines that 
promote elimination such as CD8+ cytotoxic T cells, NK cells, T-helper 1 (Th1), 
or DC while other cells promote tumor progression (Th2, and Foxp3+ regulatory 
T [Terg]). In addition, the tumor microenvironment sends concomitant dangerous 
signals to the host immune system (as inflammatory, hypoxic, and often necrotic 
microenvironment). B cells and plasma cells can also adopt a positive or negative 
antitumor associations depending on contextual factors.
Therefore, infiltrating immune cells can function to control tumor growth, but 
can also help to create an immunosuppressive environment in which the tumor can 
progress (Fig 2). 
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Some cancers present hundreds or even thousand mutations, representing a 
large repertoire of antigens that could be recognized by the immune system. But 
despite expression of abundant antigens, most cancers progress and evade immune 
system. Many immune escape mechanisms have been identified, including local 
immune suppression, induction of tolerance, dysfunction in T-cell signaling, and 
evasion of immune destruction by expression of endogenous “immune checkpoint” 
that normally terminate immune responses after antigen activation57. 
Fig. 2. The cellular cross-talk between different leukocyte subsets and their predominant 
contribution to either pro- or antitumor activities, including myeloid lineage leukocytes, tumor-
associated macrophages with either protumorigenic (M2) or antitumorigenic (M1) properties, helper 
T-cell subsets, cytotoxic T cells, regulatory T cells, B cells, dendritic cells and myeloid-derived 
suppressor cells are shown. These cells play central roles in shaping the microenvironment via the 
factors they produce thereby driving either an immune-mediated anti- or protumor activities in the 
microenvironment.
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Although patients are most frequently diagnosed in the escape phase, even at 
these advanced disease stages, immune parameters have been recognized as directly 
or indirectly influencing patient survival. The exact composition of the immune 
infiltrate can vary widely within and between tumors and modulate the effectiveness 
of the antitumor response. It seems that adaptive immunity mediated by T and B 
lymphocytes provides the critical foundation for effective and sustained antitumor 
responses. Therefore, defining these immune phenotypes may aid in predictive 
biomarker development for classes of immunotherapy.
  
In breast cancer, tumor infiltration by cytotoxic CD8+ T cells was strongly 
associated with patient survival, and response to therapy. The presence of CD4+ 
regulatory T cells (Treg) has been associated with both good and bad prognosis. 
Among the other CD4+ T-cell subpopulations, Th1 cells (the principal cellular source 
of interferon-γ) have been associated with favorable clinical outcomes, whereas Th2 
cells have been reported to be associated with dampening of the antitumor response. 
Th17 cells, producers of the proinflammatory IL-17, appear to have variable effects 
depending on the surrounding cytokine milieu, which may in part be linked with the 
organ site and tumor type. The precise role of tumor-infiltrating B cells is currently 
not well defined and remains controversial.
Despite the heterogeneity of intratumor lymphocytes it is interesting that the 
degree of tumor-infiltrating lymphocytes (TILs) has shown to have prognostic 
and predictive value in HER2+ and TNBC in spite of a lack of information on the 
immune subpopulations. 
Thus, despite the inability of the immune system to reject a clinically detectable 
tumor, an organized immune response at the tumor site may signal the generation 
of immunological memory with the potential to effectively control residual disease. 
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Different methods to evaluate the host immune response
Flow cytometry is a common approach to immune cell profiling and it is able to 
characterize immune cell subsets by multiple markers, quantitative data acquisition, 
wide availability, and possess also the ability to examine small subpopulations of 
interest. However, fresh tissue is required and no information is provided on the 
organization of the immune infiltrate or relationship to other microenvironmental 
structures. Nevertheless, recent study of TILs in invasive breast carcinoma found 
a significant positive correlation between fresh tumor tissue analyzed by flow 
cytometry and IHC-stained sections. Nowadays, a semiquantitative H&E-based TILS 
assessment provides clinically relevant information. This technique is affordable and 
accessible.
Another way to evaluate the immune context of cancer is studying mRNA 
profiling of tumor tissue. By doing that, it is possible to detect “immune signatures”, 
using the level of expression of immune-related genes to describe the composition 
and functional status of the immune infiltrate58. No information is provided on the 
distribution of the infiltrate with this method furthermore this technology is currently 
restricted to a research setting. This method is more complex and more difficult to be 
implemented in clinical practice. 
Immunotherapy in Breast Cancer 
Recently, new therapies that reactivate anticancer immune responses to cancer 
have been introduced in clinical practice improving clinical outcomes and several 
studies are on-going to evaluate new drugs and combinations. Clinical trials have 
demonstrated durable responses in different solid tumors, nevertheless, the benefit 
within tumor types vary widely. 
One of the most studied mechanisms leading to tumor immune evasion is 
the expression of immune checkpoint molecules such as cytotoxic T lymphocyte 
antigen-4 (CTLA4) and programmed death ligand-1 (PD-L1), both on tumor cells 
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and on infiltrating immune cells. By blocking these signaling pathways, immune 
checkpoint inhibitors can reactivate the host immune system to recognize and control 
the tumor cells.   
A particular challenge in immunotherapy is the identification of predictive 
biomarkers to discern responders from non-responders and to guide disease-
management decision. For this reason, there is a strong need in identifying consistent, 
largely applicable, and clinically validated biomarkers. 
Emerging data suggest that patients whose tumors overexpress PD-L1 by 
IHC have improved clinical outcomes with anti-PD1-directed therapy tumors. 
Nevertheless, the role of PD-L1 expression and its relation with response to 
checkpoint inhibitors is actually controversial. 
Interestingly, in breast cancer, TILs were shown to correlate with pathological 
complete response (pCR) after neo-adjuvant chemotherapy in all breast cancers. 
However, a significant correlation between TILs at diagnosis and overall survival 
was only observed in TNBC and HER2. 
Immune genes expression 
The development of gene expression profiling of tumors has enabled to identify 
prognostic gene expression signatures and patient selection for targeted therapies. 
Recently several studies have evaluated the association of immune-related gene 
expression in patients with different solid tumors treated with immunotherapy. 
Among them, the IFN-inflammatory immune gene expression signature was 
associated with both enhanced overall response (OR) rates and PFS in patients 
with melanoma treated with an anti PD-1 monoclonal antibody, pembrolizumab59. 
Another examples of signature predicting response to immunotherapy, includes an 
eight-gene signature reflecting preexisting immunity, the T-effector/IFNγ signature, 
explored in a phase II trial of previously treated non–small cell lung carcinoma60. 
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If validated, the implementation of these or others signatures will require the use 
of robust and reproducible genomic-based platforms to select treatment in clinical 
practice.
According to all these considerations, we have to assume, that we are at the 
beginning of a new paradigm in breast cancer therapy. However, at present, the 
biologic diversity of breast cancer remains elusive. Futhermore, the burden of 
mutations is lower in breast cancer than in classically immunologically tractable 
cancers, such as melanoma or lung cancer, and breaking immune tolerance appears 
to be more difficult.
b. Chromosomal instability
Chromosomal instability (CIN) results in alterations in chromosome number 
or structure, developing intercellular genetic heterogeneity and therefore intratumor 
heterogeneity. Numerical CIN is characterized by gain or loss of whole chromosomes 
(aneuploidy), while structural CIN is characterized by gain or loss of fractions of 
chromosomes.
 
This alteration is a hallmark of solid tumors, and it has been implicated in 
tumor evolution, increased invasiveness, poor prognosis and, therapy resistance. 
Furthermore, it has been reported that CIN is highest in the most aggressive and 
metastatic cancer types 
Breast cancer has different patterns of chromosomal alterations, as there are 
some DNA amplifications associates with the Luminal B and HER2-E subtypes. 
One of the most notable and classic examples is amplification of HER2, but there 
are other amplified sites that include FGFR1, MYC, CCND1, MDM2, and ZNF21761. 
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Finally, CIN in breast cancer has been correlated with higher tumor grade, 
poorer survival and shorter times to recurrence. These observations suggest that CIN 
have important clinical implications. 
Nevertheless, modest level of genetic diversity provides an advantage in 
tumors, excessively high rates of CIN cause tumor death, as inviable progeny. These 
considerations suggest that cancer cell to survive needs a balance and an optimal 
range of CIN (Fig. 3).
Fig. 3. High levels of CIN cause excessive chromosome loss and cell death, whereas modest levels of 
CIN provide sufficient genetic diversity for cancer. 
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A deeper understanding of the characteristics associated with CIN and the 
development of clinically applicable biomarkers are needed both for patient 
stratification and to leverage new therapeutic opportunities.
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HYPOTHESIS 
Most biological changes occur during metastatic progression of breast cancer. 
Thus, we hypothesized that there is a different biology behavior between primary 
and metastatic breast cancer. For this reason, we proposed a transcriptomic approach 
in paired primary and metastatic tissues from a cohort of metastatic breast cancer 
patients.
OBJECTIVES 
Aim 1. To characterize metastatic disease and analyze the PAM50 subtypes between 
PT and MT 
Aim 2. To analyzed the gene expression changes between PT and MT
Aim 3. To explore the role of chromosomal instability in the metastasis process
Aim 4. To explore the implication and changes of immune-system gene expression 
between both setting
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1. Study population
This retrospective study included non-consecutive female patients over the age 
of 18 years with a histologic diagnosis of metastatic breast cancer detected at the time 
of diagnosis, at first relapse or after successive disease progressions. Tissues were 
collected from five independent sources: GEICAM/2009-03 ConvertHER trial62, 
Hospital Clínico Universitario de Valencia, Vall d’Hebrón Institute of Oncology, 
University-AO Papardo and Hospital Clinic of Barcelona. To be included, samples 
were required to have a formalin-fixed paraffin-embedded (FFPE) tissue sample from 
primary and metastatic tumor. Biopsies were performed by core biopsy or surgical 
process, according to the routine clinical practice of the hospitals. For each sample, 
receptor status (ER, PR, and HER2) were analyzed at the local laboratory.
2. Gene expression analysis and gene list
All primary and metastatic tissues were analyzed using the same methodology. 
A section of FFPE breast tissue was first examined with a hematoxylin and eosin 
staining to confirm the diagnosis and determine the tumour surface area. For RNA 
purification, three 10-μm FFPE slides were cut for each tumor, and macro-dissection 
was performed, when needed, to avoid normal breast contamination. A minimum 
of approximately 100 ng of total RNA was used to measure the expression of 105 
breast cancer-related genes and 5 housekeeping genes (ACTB, MRPL19, PSMC4, 
RPLP0, and SF3A1) using the nCounter platform (Nanostring Technologies)63. Data 
was log base2–transformed and normalized using the housekeeping genes. Raw data 
have been deposited in the Gene Expression Omnibus under the accession number 
GSE92977.
The list of 105 breast cancer–related genes includes genes from the following 
three signatures: PAM50 intrinsic subtype predictor (n = 50)64, claudin-low subtype 
predictor (n = 43)65, VEGF/Hypoxia signature (n = 13)66. In 8 addition, we included 
individual genes that have been found to play an important role in breast cancer [i.e., 
CD2467, CRYAB68, ERBB469, PIK3CA70, PTEN, RAD1771, RAD50, and RB1]. In 
the following table, there is the complete list of genes: 
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We analyzed the RNA sequencing (RNAseq) in 102 patients of this corhot. 
RNAseq had been used to identify biomarkers related with immune cells and 
chromosomal instability (CIN7072). We assessed 16 immune-related signatures73 74 
[i.e., CD8+ T, Th2 cells, innate immune, macrophages, NK cells, neutrophils, dendritic 
cells, mastocytes and B and T cells] and CIN (Table 2). In addition, we evaluated the 
following 6 immune-related genes including: CD4, CD274, CTLA4, CD8A, CD45, 
and PDCD1.
Table 1. List of 105 breast cancer-related genes.
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Table 2. List of gene signatures.
40 · Primary and metastatic breast cancer
3. Intrinsic subtype and Cluadin-low intrinsic subtype
All tumors were assigned to an intrinsic molecular subtype of breast cancer 
(luminal A, luminal B, HER2-E, and basal-like) and the normal-like group using 
the previously reported PAM50 subtype predictor75. Also, we applied the previously 
reported 9-Cell line claudin-low predictor76. Only a sample was identified as claudin-
low independently of the PAM50 subtype call. 
4. Gene signatures
The expression of 10 independent signatures was evaluated as a continuous 
variable. The PAM50 predictor calculates, for each sample, the correlation coefficient 
to each of the 5 PAM50 centroids (luminal A, luminal B, basal-like, HER2-enriched, 
and normal-like). Each centroid was considered a single signature. In addition, the 
PAM50 predictor outputs a risk of recurrence (ROR) score at 10 years. The ROR score 
based on subtype (ROR-S) and subtype and proliferation (ROR-P) were developed 
in a micro-array-based cohort of node-negative, untreated early breast cancer77. In 
addition, we evaluated the following three signatures: proliferation score, which is 
the mean expression of 11 proliferation-related genes78, VEGF/Hypoxia signature79, 
which is the mean expression of 13 hypoxia-related genes, and claudin-low signature 
(as a continuous variable)80.
5. Statistical analysis
χ2 tests were performed to determine the differences in the distribution of 
variables. To identify genes whose expression was significantly different between 
paired primary and metastatic samples, we used a paired two-class significance of 
microarrays (SAM) with a false discovery rate (FDR) <5% (35). Biologic analysis 
of gene lists was performed with DAVID annotation tool (http://david.abcc.ncifcrf.
gov/; ref. 36). Time to tumor recurrence (TTR) was defined as the period of time 
from surgery to the date of the first distant relapse. Overall survival from metastatic 
disease (OSmet) was defined as the period of time of metastatic disease to death 
or last follow-up. Estimates of survival were from the Kaplan–Meier curves and 
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tests of differences by the log-rank test. Univariate Cox models were used to test 
the independent prognostic significance of each variable. All statistical computations 
were carried out in R v2.15.1 (http://cran.r-project.org). All statistical tests were two 
sided, and the statistical significance level was set to less than 0.05.
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1. Intrinsic Subtypes and gene expression profiles in primary and metastatic 
breast cancer
a. Clinical–pathologic characteristics
A total of 123 patients were included (Table 3). The median age at breast cancer 
diagnosis was 52.5 years (range, 28–90). In primary disease, the immunohistochemical 
analyses showed 73.17% (n = 90) of patients had HR-positive (HR+), 15.45% (n = 19) 
HER2-positive (HER2+), and 9.76% (n = 12) triple-negative disease. In metastatic 
disease, 69.92% (n = 86) of patients had HR+, 19.51% (n = 24) HER2+, and 9.76% 
(n = 12) triple-negative disease. No significant differences (P > 0.502) were observed 
in the distribution of the three IHC groups in primary versus metastatic disease. 
Fourteen patients (11.38%) presented with de novo metastatic disease. Median 
follow-up and OSmet were 76.5 and 84 months, respectively (Fig. 4)
Table 3. Clinical characteristics of the cohort.
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Fig. 4. Overall survival from recurrence to death or last follow-up of the entire cohort.
b. Type of metastatic tissues
The organs of origin of the metastatic biopsies analyzed in this study were 
skin (n = 35; 28.4%), lymph nodes (n = 24; 19.5%), liver (n = 20; 16.3%), bone 
(n = 16; 13%), lung (n = 7; 5.7%), ovarian and peritoneum (n = 7; n = 5.7%), pleural 
(n = 6; 4.9%) and others (n = 8; 6.5%), including brain, pericardial fluid, and colon 
metastases (Fig. 5).
Fig. 5. Organs of origin of the metastatic biopsies.
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c. Subtype distribution
The distribution of the PAM50 intrinsic subtype classification in primary tumor 
versus metastatic disease was 39% versus 26% for luminal A (P = 0.029), 26% versus 
35.8% for luminal B (P = 0.097), 11.4% versus 22% for HER2-E (P = 0.026) and 
9.8% versus 12.2% for basal-like tumors (P = 0.540) (Fig. 6).
Fig. 6. Distribution of intrinsic subtype in primary versus metastatic disease.
Individually, subtype concordance was high for basal-like (100%), HER2-E 
(76.9%), and luminal B (70.0%) tumors. Regarding luminal A primary tumors, 44.7% 
remained luminal A in the metastasis, switching to luminal B in 40.4% and HER2-E 
in 14.9% of the cases. Overall, primary luminal tumors (A and B combined) changed 
to a HER2-E in 14.28%, despite 81% of them being clinically HER2 negative. Cohen 
kappa coefficient was 0.38 [95% confidence interval (CI), 0.27–0.5, P < 0.001] 
(Table 4). 
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Fig. 7. HER2 and FGFR4 mRNA expression changes between HER2-negative/Luminal A-B primary 
and HER2-negative/HER2-E metastasis breast cancer.
Table 4. Subtype concordance between primary and metastatic disease. *, FDR, false discovery rate.
Indeed, we observed that the 8 patients, whose tumors changed from luminal 
A/B in primary disease to HER2-E in metastatic disease showed an increase 
in FGFR4 expression but not ERBB2 expression (Fig. 7).
These results did not changed when the claudin-low classification was investigated 
as no claudin-low tumor was identified in this series. Finally, we observed that liver 
and lung metastases showed the highest and lowest subtype conversion rate (75% 
and 14%), respectively. However, these results by site of metastasis need further 
validation, due to the small sample sizes (Table 5).
48 · Primary and metastatic breast cancer Results · 49
Table 5. Different Intrinsic subtype conversion across the different organs of metastasis.
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Fig. 8. Gene and signature expression changes between primary and metastasis. P value was obtained 
after performing a paired t test.
d. Expression changes of individual signatures
We evaluated the expression changes of each individual signature between 
primary tumor and their paired metastatic samples. Luminal A and normal-like 
signatures were found significantly less expressed in metastatic tumors than in 
primary tumor. In contrast, luminal B, HER2-E, and proliferation signatures were 
found more expressed in metastatic tumors than in primary tumors. Finally, the 
expression of basal-like, VEGF/hypoxia and claudin-low signatures was similar 
between primary and metastatic disease (Fig. 8).
e. Expression changes of individual genes
Among 105 breast cancer–related genes, 16 and 31 genes were found up- and 
downregulated in metastatic tissues compared to primary tissues (FDR < 5%) 
(Table 6). The upregulated gene list was enriched for genes involved in survival and 
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migration (e.g., FGFR4), cell cycle (e.g., CDC6 and CCNB1), and DNA repair (e.g., 
TYMS). The downregulated gene list was enriched for genes involved in response to 
hormone stimulus (e.g., BCL2 and PGR; Fig. 7), differentiation (e.g., GATA3) and 
chromatin regulation (e.g., CXXC5).
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A similar analysis was performed within each of the subtypes identified in 
primary disease. Concordant with the subtype changes, 25, 8, 7, and 0 genes were 
found differentially expressed in luminal A, luminal B, HER2-E, and basal-like 
primary disease, respectively, compared with metastatic disease (Table 7).
Table 6. List of up- downregulated genes differentially expressed between metastatic vs. primary 
disease across all samples (FDR<5%).
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Table 7. List of up- and downregulated genes differentially expressed between metastatic vs. primary 
disease across all samples by intrinsic subtype.
f. Association with overall survival
We also evaluated the ability of the 10 signatures to predict OSmet in primary 
(Fig. 9A) versus metastatic (Fig. 9B) disease. Interestingly, no signature consistently 
predicted OSmet in both primary and metastatic disease. In primary disease, 
basal-like signature was found associated with worse outcome (HR = 1.50, P = 
0.007), while the VEGF/Hypoxia signature was associated with a better outcome 
(HR = 0.65, P = 0.016). In metastatic disease, proliferation was found associated 
with worse outcome (HR = 1.40, P = 0.047).
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Fig. 9. Association of 10 signatures with OSmet when evaluated in primary (A) and metastatic (B) 
disease. Each signature was evaluated as a continuous variable and was standardized to have a mean 
of 0 and a SD of 1. The size of the square is inversely proportional to the SE; horizontal bars represent 
the 95% Cls of HRs. Statistically significant variables are shown in blue. Each gene signature was 
evaluated in a univariate analysis.
These results suggested that OSmet might be better predicted by measuring 
either the primary tumor or the metastatic tumor depending on the biological process 
(e.g., proliferation) being evaluated. To further explore the role of this signature, 
we evaluated the ability of each individual gene to predict OSmet in primary versus 
metastatic disease. Among 105 genes, 14 and 10 genes were finally found associated 
with OSmet in primary and metastatic disease, respectively. Interestingly, only one 
gene (GATA3) consistently predicted favorable outcome in both settings (Fig. 10). 
In primary disease, high expression of 13 of the 14 genes was found associated 
with better outcome. These 13 genes (e.g., PGR, ESR1, and FOXA1) were mostly 
tracking luminal-related biological processes. On the contrary, high expression of 
8 of the 10 genes in metastatic disease was found associated with worse outcome. 
These 8 genes (e.g. MYC, CCNE1, and CCNB1) were mostly tracking cell cycle/
proliferation-related biological processes.
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Fig. 10. Venn diagram of genes that predict overall survival from the data of recurrence when 
analyzed in primary versus metastatic disease. Green, genes associated with good prognosis; red, 
genes associated with poor prognosis.
Finally, we explored the ability of each gene signature to predict OSmet in 
patients with tumors with no subtype conversion (n = 59) versus patients with 
tumors without subtype conversion (n = 49). The results revealed that in patients 
with no subtype conversion, the association profile of signatures with OSmet were 
very similar when the primary or the metastatic tumors were evaluated. However, 
in patients with subtype conversion, the associations of signatures with OSmet 
were generally different when the primary or the metastatic tumors were evaluated. 
Among them, the HER2-E signature was found significantly associated with poor 
outcome (HR = 1.86, P = 0.046) when evaluated in metastatic tumors but not when 
evaluated in primary disease (Fig. 11).
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Fig. 11. Association of 10 signatures with OSmet when evaluated in primary metastatic disease with 
subtype conversion vs. without subtype conversion.
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g. Magnitude of gene expression changes versus TTR
To evaluate if the gene expression changes observed in metastatic tissues are 
a reflection of tumor evolution over time, we plotted the magnitude of change 
of the expression of each signature versus TTR (Fig. 12). The results revealed a 
positive correlation between TTR and HER2-E (corr = 0.324, P < 0.001), luminal 
B (corr = 0.27, P = 0.004), Proliferation score (corr = 0.291, P = 0.002), and ROR-P 
(corr = 0.295,P = 0.001). In contrast, normal-like and luminal A signatures showed a 
negative correlation with TTR (corr = −0.285, P = 0.002; corr = −0.219, P = 0.019, 
respectively).
Fig. 12. Correlation between time to tumor recurrence (TTR) and the magnitude of gene/signature 
expression changes between primary and metastatic disease.
Gene-by-gene analysis revealed a positive correlation between TTR and 
the magnitude of change of genes implicated in cell proliferation (CEP55: corr = 
0.244, P = 0.024), mitogenesis, and differentiation biological process (FGFR4: corr 
= 0.211, P = 0.044). In contrast, a negative correlation was observed with genes that 
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participate in cell-to-cell adhesion (CLDN4: corr = −0.207, P = 0.027; F11R: corr = 
−0.237, P = 0.01), regulation of DNA damage repair (RAD17: corr: −0.226, P = 0.017), 
tumor suppression (GRHL2: corr = −0.186, P = 0.05), mammary gland development 
(PGR: corr = −0.203, P = 0.045), and that attenuate cell migration (ESRP1: corr = 
−0.252, P = 0.006).
h. Conclusions
Here, we explored RNA-based expression differences between paired primary 
and metastatic breast tumors and made the following observations: (I) intrinsic 
molecular subtype is largely maintained during metastatic recurrence, except for 
luminal A disease, which converted to luminal B and HER2-enriched in 55% of 
the cases; (II) metastatic tissues show higher expression of proliferative and lower 
expression of luminal-related genes compared to primary tumors, except for basal-
like disease, which seems to be very stable from a RNA-based perspective; (III) 
different biological processes can predict overall survival from recurrence when 
evaluated in primary versus metastatic disease; (IV) an intriguing relationship 
seems to exist between the time taken to develop detectable metastases and the 
aggressiveness of the tumor, indicating that a tumor might evolve towards a more 
aggressive phenotype as time evolves.
Previous studies have evaluated the rates of change of the three classical 
pathologic biomarkers (i.e., ER, PR, and HER2) between primary and metastatic 
tumors81 82. Overall, the rates of ER, PR, and HER2 conversion were 13%, 28%, 
and 3%–10%, respectively83. Among the three genes, we also observed PGR as the 
top downregulated gene in metastatic compared with primary tissues. Nonetheless, 
the three classical biomarkers are largely maintained in the metastatic setting, which 
is concordant with our findings using the basal-like, HER2-enriched, and luminal 
A/B intrinsic subtype classification. At the same time, prior gene expression-based 
studies with smaller number of patients are concordant with our findings84 85 86. 
However, Lee and colleagues evaluated the PAM50 intrinsic subtypes in 17 paired 
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samples of primary and brain metastasis, and subtype conversion was observed in 
47.1% of the cases, which is higher than the 30.9% conversion rate observed in our 
study. However, similar to our study, a large proportion of luminal A primary tumors 
(1/6) changed to non-luminal A disease, and all basal-like primary tumors (n = 6) 
remaining basal-like at recurrence87.
Other studies have evaluated changes in somatic mutations and gene copy-
number aberrations (CNA) between primary and metastasis. For example, Meric-
Bernstam and colleagues88 performed targeted DNA sequencing of 3,320 exons 
of 182 cancer-related genes plus 37 introns from 14 genes in 74 tumors. In 33 
matched primary and recurrent tumors, 97 of 112 (86.6%) somatic mutations were 
concordant. Of identified CNAs, 136 of 159 (85.5%) were concordant. There was 
an increased frequency of CDK4/MDM2amplifications in recurrences, as well as 
gains and losses of other actionable alterations. The authors concluded that analysis 
of recurrent tumors before treatment may provide additional insights, as both gains 
and losses of targets are observed. In another study, Ding and colleagues described 
the genomic analyses of four DNA samples from an Africo-American patient with 
basal-like breast cancer: peripheral blood, the primary tumor, a brain metastasis, and 
a xenograft derived from the primary tumor. Of the 50 validated point mutations and 
small indels, 48 were detectable in all three tumors. Overall, while additional somatic 
mutations, copy number alterations, and structural variations occurred during the 
clinical course of the disease, most of the original mutations and structural variants 
present in the primary tumor were propagated.
Similar to prior studies looking at DNA alterations, we did not identify large 
absolute expression changes at the RNA level between primary and metastatic 
disease. Nevertheless, 47 genes were found differentially expressed, mostly within 
luminal A/B disease. Among them, FGFR4 was detected as the top upregulated 
gene in metastatic disease. Interestingly, this gene is found in the PAM50 gene list 
and its overexpression is characteristic of the HER2-E intrinsic subtype. Fibroblast 
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growth factor receptors are involved in development, differentiation, cell survival, 
migration, angiogenesis and carcinogenesis89. Dimerization of the receptor leads 
to intracellular phosphorylation of receptor kinase domains and intracellular signal 
transduction, including RAS/RAF/MEK and PI3K/AKT pathways90. These evidences 
suggest that FGFR4 could drive the HER2-E phenotype in metastatic lesions with 
a HER2-negative/HER2-E profile. Indeed, the patients whose tumors changed from 
luminal A/B in primary disease to HER2-E in metastasic disease showed an increase 
in FGFR4 expression but not ERBB2 expression. Of note, HER2-E subtype has 
been associated with estrogen-independent growth and poor outcome in patients 
with HR+/HER2-negative breast cancer treated with anti-estrogens91 92. Further 
mechanistic studies are needed to elucidate the role of FGFR4 in metastatic disease.
Currently, large-phase III clinical trials, especially within HR+/HER2-negative 
disease, are not taking into account this biological heterogeneity, such as proliferation, 
which is not well captured by HR and HER2 statuses. For example, patients with 
a luminal A profile following endocrine therapy might be treated with second-line 
endocrine therapy while those that change to a HER2-negative/HER2-E or luminal 
B profile might be treated with chemotherapy or other novel combinatory strategies 
such as endocrine therapy andCDK4/6 inhibition. Overall, this result suggests that, 
although there is some stability of the intrinsic subtype, approximately 40% of the 
tumors will change subtype, highlighting the need to biopsy metastatic disease to 
better understand the clinical and biological evolution of a tumor.
Another interesting observation was the significant correlation between the 
magnitude of gene expression changes of various signatures between primary and 
metastasis disease and the time from diagnosis to tumor recurrence. Specifically, we 
observed that the longer was the time to recurrence, the more aggressive the tumors 
become based on proliferation and expression of luminal genes. This suggests that 
there is an intrinsic evolution of tumor cells towards a more aggressive phenotype as 
time elapses. However, the correlation coefficients were weak and thus the magnitude 
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of gene expression changes might also be explained by other variables such as the 
treatments received in (neo)adjuvant setting.
Despite the interesting founding, this study has several limitations worth noting. 
First, this is a retrospective study using tumor samples from different hospitals and 
a selection bias is plausible. Second, patients received different adjuvant and/or 
metastatic systemic treatments and thus we could not evaluate treatment effects on 
tumor biology or survival. However, subtype conversion of the 14 patients with de 
novo metastatic disease was found to be 57.1%, suggesting that subtype conversion 
is independent of treatment effects. For all these reasons, more studies are needed 
to address this particular question. Third, metastatic tumor biopsies were not always 
collected at the time of the diagnosis of recurrent disease. Fourth, we did not analyze 
DNA mutations such as ESR1 whose incidence is known to increase during tumor 
progression. Further studies will be able to evaluate if the gene expression changes 
observed during progression of luminal breast cancer are related to the appearance 
of ESR1 mutations.
To conclude, most biological changes occurring during metastatic progression 
of breast cancer are largely unknown today. Here, we compared intrinsic molecular 
subtype and expression of individual genes in paired primary and metastatic tissues. 
Our results suggest that although intrinsic subtype is largely maintained during 
metastatic progression, luminal/HER2-negative tumors acquire a luminal B or 
HER2-E profile during metastatic progression, likely reflecting tumor evolution and/
or acquisition of estrogen-independency. 
2. Immune-related genes expression profiles
The aim of this analysis is to assess the prognostic value and changes of 
immune-related genes expression profiles across intrinsic molecular breast cancer 
subtypes. Furthermore, we explored how immune signatures evolve during disease 
progression. 
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Table 8. Clinical characteristics of the cohort with 
RNA-seq analysis.
a. Clinical-pathologic characteristics and subtypes distribution
A total of 102 patients were included in this analysis. The median age at 
breast cancer diagnosis was 52.5 years (range, 28–90). In primary disease, the 
immunohistochemical analyses showed 74.5% (n = 76) of patients were luminals, 
15.7% (n = 16) HER2-positive (HER2+), and 7.8% (n= 8) triple-negative disease. In 
metastatic disease, 70.6% (n = 72) of patients were luminals, 18.6% (n= 19) HER2+, 
and 8.8% (n= 9) triple-negative disease. Median OS was 85.5 months (Table 8).
The distribution of the PAM50 intrinsic subtype classification in primary tumor 
versus metastatic disease was 39.22% versus 26.47% for luminal A, 28.43% versus 
34.31% for luminal B, 11.76% versus 23.53% for HER2-E and 7.84% versus 10.78% 
for basal-like tumors (Fig. 13).
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Fig. 13. Distribution of intrinsic subtypes in primary versus metastatic disease.
Individually, subtype concordance was high for basal-like (100%), HER2-E 
(66.67%), and luminal B (62.07%) tumors. Regarding luminal A primary tumors, 
45% remained luminal A in the metastasis, switching to luminal B in 37.5% and 
HER2-E in 15% of the cases. Overall, primary luminal tumors (A and B combined) 
changed to a HER2-E in 14.49%, despite 70% of them being clinically HER2 
negative. (Table 9).
Table 9. Subtype concordance between primary and metastatic disease. 
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b. Immune-related genes expression across intrinsic molecular breast cancer 
subtypes
We performed an analysis of 6 immune-related genes (CD4, CD8A, CD45, 
CTLA4, PDCD1 and CD274) across intrinsic molecular breast cancer subtypes in 
primary and metastatic samples. 
Very similar patterns of immune-related gene expression were observed between 
both settings. Where Basal-like group showed the highest expression followed by 
HER2-E. While Luminal subtypes presented less gene expression in both early and 
advanced disease (Fig. 14).
Fig. 14. Expression of 
selected genes across 
the molecular intrinsic 
subtypes of breast cancer 
in primary (left) and 
metastatic (right) tumor.
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We performed an analysis of several immune signatures using public available 
data from transcriptional profile of immune cell subpopulations. When we analyzed 
the expression of these immune signatures across the intrinsic subtypes, most of 
them, including T and B cells, and macrophages, they were found to be upregulated 
in Basal-like in both primary and metastatic tumor (Fig. 15). 
Fig. 15. Expression of 
immune signatures across 
the molecular intrinsic 
subtypes of breast cancer 
in primary (left) and 
metastatic (right) tumor.
To better understand the evolution of the immune response, we evaluated the 
expression changes of each gene between primary and metastatic disease. In our 
analysis, CD4 was more expressed in metastatic tumor (p= 0.016), and especially 
in Luminal A (p= 0.025) and HER2-E subtypes (p= 0.004). Interestingly, CTLA4 
and PDCD1, both immune checkpoint pathway inhibitors, were downregulated in 
the metastatic tissues. In this case, CTLA4 was found significantly less expressed in 
metastatic tumor (p= 0.009), especially in Luminal B (p= 0.011). Meanwhile, PDCD1 
presented a significant downregulation only in Luminal B (p= 0.044) (Fig. 16).
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Fig. 16. Immune- gene expression changes between primary and metastasis disease.
Finally, we explored the association between the PAM50 signatures and the 
6 immune-related genes. The results showed a positive correlation between all of 
them and Basal-like signature. In contrast, a negative correlation was found with 
Luminal A signature (Fig. 17). Luminal B signature showed a negative correlation 
with PDCD1, meanwhile HER2-E subtype presented a positive correlation with 
CD4 (Fig. 17). 
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Fig. 17. Correlation between 6 immune-related genes and PAM50 signatures.
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Similar data were observed when we analyses the relation between PAM50 
and immune signatures. Basal-like and HER2-E showed a positive correlation, in 
contrast, Luminal A and B presented a negative correlation with immune signatures 
(Fig. 18).  
Fig. 18. Correlation between immune signatures and PAM50 signatures. 
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To gain deeper insights the complex spatiotemporal dynamics of the tumor-
immune interaction during tumor progression, we investigated both innate immune 
cell (dendritic cells, mast cells, macrophages, NK cells, and neutrophils) and adaptive 
immune cells (B, T helper 1, T helper 2, T γ δ).   
Innate immune signature was significantly higher expressed in metastatic tissue 
vs primary samples in the global cohort (p= 6.1e-1). We found some subpopulation 
cells upregulated such as dendritic cells (p= 9.68e-6), Th2 (p= 0.006), and Th1 
(p=0.024). 
When we assessed the signatures across PAM50 subtypes, we found a significant 
upregulation of innate immune system in Luminal A (p= 1.19e-4) and HER2-E (0.002) 
tumors in the metastatic disease. When we focused in immune subpopulations cells, 
we found dendritic cells (p= 0.005), macrophages (p= 0.005), and Th2 (p= 0.004) 
upregultaed in Luminal A. And also, dendritic cells (p= 0.011), macrophages and 
Th1 (p= 0.018), Tgd (p= 0.039), cytotoxic cells (p= 0.038), antigen presentation 
(p= 0.013), and macrophages (p= 0.002) signatures were upregulated in HER2-E 
(Fig. 19).
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Fig. 19. Innate immune signatures expression change between primary and metastasis. P value was 
obtained after performing a paired t test
c. Immune-related genes expression associated with prognostic value 
Additionally, we tested the ability of the 6 immune-related genes to predict 
prognosis in primary versus metastatic setting. Of note, no single gene consistently 
predicted prognosis in both primary and metastatic disease. Furthermore, no single 
gene predicted DFS by measured at primary tumor.
In metastatic disease, CD274, CD8A and CD4 were found to be associated with 
better outcomes in terms of OS (HR= 0.51, p= 0.003; HR= 0.63, p= 0.026; HR= 
0.72, p= 0.039; respectively). However, in primary tumor none of these genes were 
related with survival (Fig. 20).
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Fig. 20. Association of 6 immune-related genes with OS evaluated in primary (A) and metastatic (B) 
disease.
All innate immune signatures were associated with good prognosis in terms of 
OS in the metastatic group (HR<1, p< 0.05). Adaptive immunity mediated by T and 
B lymphocytes are crucial for effective and sustained antitumor responses. In this 
case only Th2 was related with worse outcome in primary tumor (OS, HR: 1.56, p= 
0.048)  (Fig. 21).
Fig. 21. Association of immune signatures with OS when we evaluated in primary and in metastatic 
disease. 
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Furthermore, CD8+ T cell was associated with favorable overall survival in 
metastatic disease when we measured in metastatic tissue (Osmet, HR: 0.66, p= 
0.04).
    
d. Conclusions
The immune microenvironment of breast cancer differs according to tumor 
biology. In summary, our data propose that the expression of immune genes varied 
significantly between different intrinsic subtypes. These observations were based on 
assessment of immune-related genes expression.
We showed an inverse correlation between luminal tumors and immune 
genes. Therefore, Basal-like followed by HER2-E were more immunogenic than 
luminal breast cancer subtypes. This suggests that luminal breast cancer is more 
immunologically “cold” than non-luminal, and thus, luminal tumors would be 
immunologically silent. 
Interestingly, controversial data regarding the literature was found, because 
metastatic tumors presented more immunoreactivity than primary tumors. 
Our results also add the utility of RNA-based immune biomarkers for predict 
prognosis. There was a robust association between immune genes expression 
measured at metastatic tumors and favorable patient outcomes, in contrast, this effect 
was not found in primary tumor. Only Th2 cells were related with bad prognosis, 
these cells has been widely described as promoting metastasis and it was related to 
worse overall survival.
3. Chromosomal instability
One of the most consistent characteristics of human tumors is CIN. Despite 
the important role in cancer biology, the molecular mechanisms underlying CIN are 
poorly understood, and it is unfrequently evaluated in the clinic due to the technical 
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difficulty and a lack of clear therapeutic application. To evaluate the role of CIN 
in breast cancer, we used a gene expression signature of chromosomal instability 
published in Nature Genetics (Carter SL, et al. Nature Genetics. 2006). 
a. CIN signature expression between paired primary and metastatic samples
We evaluated the expression changes of chromosomal instability signature 
between primary and metastatic samples. We found a global significantly enrichment 
in the metastatic setting (p= 2.11 e-3), this increased expression of CIN70 signature 
was especially due to Luminal A subtype (p= 6.74 e-4) (Fig. 22 A and B). 
When we focused the analysis in Luminal A patients in the primary tumor, we 
observed that the increase expression was associated with patients whose tumors 
switched the subtype in the metastasis to Luminal B or HER2-E (p= 2.18 e-8) 
(Fig. 22 C).
Fig. 22. CIN70 signature expression changes between primary and metastasis (A). CIN70 signature 
expression changes in Luminal A patients at primary tumor (B). CIN70 expression in metastatic 
biopsies derived from primary luminal A patients: differences between luminal A vs non-luminal A 
(C). 
Chromosomal instability was related with tumor phenotype. The most aggressive 
subtypes as Basal-like and HER2E showed the highest expression of CIN followed 
by Luminal B, while Luminal A presented less chromosomal instability expression 
in both primary and metastatic disease (p= 1.57 e-12 and p= 3.63 e-13, respectively) 
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(Fig. 23 A). Furthermore, CIN signature presented a positive correlation with RORP 
(corr = 0.82, p= 6.7 e-51) and Proliferation signature (corr = 0.812, p= 3.41 e-49). 
Interestingly, a negative correlation was observed with CESP signature (corr = -0.36, 
p= 1.79 e-24) (Fig. 23 B). 
According with these data, the highest expression of CIN70 signature was 
associated with shorter disease-free survival (p= 8.79 e-4). Furthermore, this signature 
was related with worse overall survival, but our results were not no statistically 
significant (p= 0.524) (Fig 24).
Fig. 23. Expression of CIN70 signature across PAM50 subtypes of breast cancer in primary (left) 
and metastatic (right) tumor (A). Correlation between CIN70 signature and some signatures as CESP, 
Proliferation and RORP (B).
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Fig. 24. Kaplan-Meier disease-free survival by CIN70 signature in breast cancer patients (A). Forest 
plot showing hazard ratio for overall survival related with CIN70 at primary tumor. 
b. Conclusions
CIN provides cells plasticity, due to this plasticity the cells could acquire new 
properties to develop metastasis during dormancy status and induce the change in 
breast cancer subtypes. 
Chromosomal instability could be related with phenotypic adaptation and 
produce tumor evolution, in fact, patients diagnosed with Luminal A breast cancer 
which tumor switched to luminal B or HER2E in the metastasis presented an 
increased in CIN expression. 
Furthermore, CIN70 was related with more aggressive cancer subtypes and 
represented a poor prognosis signature in terms of DFS.
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DISCUSSION
Metastasis is the main cause of death for patients with breast cancer. Many 
studies have characterized the genomic landscape of breast cancer during its early 
stages. By performing such molecular analyses, it was possible to detect that several 
genomic alterations are acquired during the evolution of cancers from their early to 
late stages. Among several genes, recently, ERBB2 and ESR1 mutations have been 
identified as acquired alteration over the course of disease93. These mutations were 
also related to acquired resistance to treatment in particular for luminal BC. 
Here, to try to further explore molecular differences, we compared a 
transcriptomic analysis performed in paired primary and metastatic tissues from 
a cohort of metastatic breast cancer patients. To do so, we explored RNA-based 
expression differences between paired primary and metastatic breast tumors. 
Our results showed different biology behavior between primary and metastatic 
breast cancer. Although intrinsic subtype was largely maintained during metastatic 
progression, it was possible to observe that luminal/HER2-negative tumors acquired 
a luminal B or HER2-E profile during metastatic progression. This switch suggests 
the tumor evolution and the acquisition of new properties of metastases.
Most cancers have an abnormal chromosomal content characterized by clonal 
changes in chromosomal structure and number. It is also know that more than 90% 
of solid tumors show some degree of genomic disbalances and are aneuploid94. The 
heterogeneity of tumors is a marker of ongoing chromosomal instability in cancer. 
CIN contributes to the transformation into a more malignant phenotype by altering 
the equilibrium between oncogenes and tumor suppressor genes, leading to the 
acquisition of new malignant properties. Gain and loss of chromosomal material in 
neoplastic cell populations provides cells plasticity that leads to the survival of the 
fittest clones. The evolution of cancer cells from benign tumor to invasive metastasis 
appears to correlate with increased aneuploidy and karyotypic complexity. 
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Therefore, CIN could be related with phenotypic adaptation and produce tumor 
evolution during metastasis disease. In our cohort of patients, those who were 
diagnosed with Luminal A breast cancer which tumor switched to luminal B or 
HER2E in the metastasis presented an increased in CIN expression signature.
Moreover, CIN has been widely associated with poor patients prognosis, 
metastasis, and resistance to chemotherapies. Indeed in our cohort, CIN was related 
with more aggressive cancer subtypes and represented a poor prognosis signature in 
terms of DFS.
Thus, understanding the mechanisms that cause chromosomal instability as well 
as mechanisms that allow genetic changes that promote acquire malignant features, 
offers an attractive possibility to interfere with tumor aggressiveness, and enhance 
the efficiency of cancer therapy.
The last aspect that we explored was the potential difference in tumor 
microenvironment and immune system between primary tumors and metastases. The 
interaction between tumor cells and stromal cells is of increasing interest and it was 
demonstrated to be crucial for both tumor progression and suppression. Cancers evolve 
through continuous interaction with immune cells in the tumor microenvironment. 
In fact, tumor-induced immunological changes causing the progression to metastatic 
disease, even before disseminated cancer cells have reached a secondary organ. 
Systemic immune tolerance and changes in the character of circulating myeloid 
cells can predispose a tumor for success in seeding a metastatic site. As tumor cells 
metastasize to distant tissue sites, they are swarmed by distinct sets of immune 
populations that can both aid in and inhibit metastasis formation95.  
Tumor-infiltrating immune cells was one of the most studied part of this 
phenomenon. TILs are supposed to play a central role in tumor control and response 
to therapy. Greater tumor infiltrating lymphocyte count and increased immune-
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related gene expression are associated with better survival in early stage triple 
negative, HER2-positive and high risk luminal breast cancer, even in the absence of 
any systemic adjuvant therapy. Which genomic features drive high or low immune 
infiltration remains unclear. 
The past decade has seen a revolution in cancer treatment with the development 
of immunotherapy towards the use of antibodies that modulate immune responses 
against tumors. The immune-checkpoint blockade (ICB) works by blocking the 
receptor and/or ligand interactions of molecules, such as CTLA-4 and PD-1 or PD-
L1. ICB therapies have shown significant clinical benefit for several solid tumors. 
Unfortunately, there is still an unmet clinical need for identify which patients could 
benefit for this target therapy . 
Detection of PD-L1 by IHC measurement has been evaluated as a predictor 
of response to anti-PD(L)-1 treatment and has been demonstrated to be a valid 
biomarker in some solid tumors. Several antibodies and pathological scores have 
been developed and used to try to identify those patients who will benefit from the 
use of an ICB. However, PD-L1 quantitation for immunotherapy response prediction 
is no longer precise and there is a need for improved biomarkers of response. 
The presence of TILs might confer a prognostic and a predictive impact. But also, 
the immune gene expression signatures represent an emerging predictive biomarker. 
In our analysis, there was a robust association between immune genes expression 
measured at metastatic setting and favorable patient outcomes, meanwhile, this 
effect was not found in primary tumor. To try to complete the evaluation of those 
factors related to immune activation in solid tumors, another parameter has been 
evaluated, the tumor mutation burden (TMB). A minority of somatic mutations in 
tumor DNA can give rise to neoantigens, which are recognized and targeted by 
immune system. The more somatic mutations a tumor has, the more neoatingens 
it is also likely to form. Importantly, this is one of the most relevant factors that 
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influence the ability of T cells to recognize and kill tumor cells. It could be logic 
to hypothesize that the tumors with the highest TMB are more likely to respond to 
immune checkpoint blockade therapy. For example, tumor mutation and neoantigen 
load predict improved PFS and OS for melanoma patients who were treated with 
adoptive T cell transfer therapy96. 
We detected differences in the immune microenvironment between primary and 
metastatic lesions and across different molecular subtypes. Our results suggest that 
immune system has different implications in primary and metastatic tumors with 
different prognostic value.
Overall, immune signatures expression was higher in metastases compared with 
primary tumors. Basal-like followed by HER2-E were the two molecular subtypes 
most immunologically active. In contrast, luminal breast cancer which presents less 
degree of difference between cancer cell and normal cell, presented less immune-
gene related expression, suggesting that luminal tumors would be immunologically 
silent. The role of immunosuppressive cells in the induction or maintenance of this 
immune suppressed state in luminals tumors warrants further investigations. 
The interaction between the tumor microenvironment and tumors is an important 
area for exploration. This knowledge could lead to different strategies for the choice 
of immunotherapy of breast cancer subtypes.  Deeper analysis of interaction between 
tumor-cells and immune-cells is likely reveal advanced biomarkers that will prove 
fruitful in identifying patients populations responsive to current immunotherapy and 
will benefit the search for novel targets for therapeutic modulation. 
Finally, our study highlights the importance of molecular characterization of 
metastatic disease. mRNA expression profiles provide a new tool to explore the 
distinct nature of breast cancer subtypes.
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CONCLUSIONS
• Intrinsic molecular subtype is largely maintained during metastatic recurrence, 
except for luminal A disease, which converted to luminal B and HER2-enriched in 
55% of the cases.
• Metastatic tissues show higher expression of proliferative and lower expression 
of luminal-related genes compared to primary tumors, except for basal-like disease, 
which seems to be very stable from a RNA-based perspective. 
• Different biological processes can predict overall survival from recurrence when 
evaluated in primary versus metastatic disease. 
• An intriguing relationship seems to exist between the time taken to develop 
detectable metastases and the aggressiveness of the tumor, indicating that a tumor 
might evolve towards a more aggressive phenotype as time evolves.
• Metastatic tumors presented more immunoreactivity than primary tumors. Where, 
Basal-like followed by HER2-E were more immunogenic than luminal breast cancer 
subtypes. This suggests that luminal tumors would be immunologically silent. 
• There was a robust association between immune genes expression measured at 
metastatic setting and favorable patient outcomes, meanwhile, this effect was not 
found in primary tumor. Only Th2 cells were related with bad prognosis. 
• Chromosomal instability could be related with phenotypic adaptation and produce 
tumor evolution. In fact, patients diagnosed with Luminal A breast cancer which 
tumor switched to luminal B or HER2E in the metastasis presented an increased in 
CIN70 expression. 
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• CIN70 was related with more aggressive cancer subtypes and represented a poor 
prognosis signature in terms of DFS.
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